Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00700102 · OUTCOME

Overall Survival: Months From Time of First Line Therapy

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. · Source last updated 2015-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
within approximately 9.6 years

Groups in this outcome

Chemotherapy

Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal

Chemotherapy + Bevacizumab

Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemotherapy410
Chemotherapy + Bevacizumab409

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy22.5Not reported2125Not reported
Chemotherapy + Bevacizumab23.9Not reported2226Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.77
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.05
    group Description
    Kaplan Meier Estimate
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.1713
    param Type
    Hazard Ratio (HR)
    param Value
    0.90
    statistical Method
    Log Rank
    tested Non Inferiority
    false
Complete source fields
analyses
  1. ci Lower Limit
    0.77
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.05
    group Description
    Kaplan Meier Estimate
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.1713
    param Type
    Hazard Ratio (HR)
    param Value
    0.90
    statistical Method
    Log Rank
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        21
        upper Limit
        25
        value
        22.5
      2. group Id
        OG001
        lower Limit
        22
        upper Limit
        26
        value
        23.9
denoms
  1. counts
    1. group Id
      OG000
      value
      410
    2. group Id
      OG001
      value
      409
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
    id
    OG000
    title
    Chemotherapy
  2. description
    Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
    id
    OG001
    title
    Chemotherapy + Bevacizumab
param Type
MEDIAN
reporting Status
POSTED
time Frame
within approximately 9.6 years
title
Overall Survival: Months From Time of First Line Therapy
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice